Top Stocks Today : IIFL Securities has Buy call on Sun Pharmaceutical Ind L - July 25
On July 25, IIFL Securities recommended buying Sun Pharmaceutical Industries Limited (Sun Pharma) shares at the current market price of Rs 1623.5. The brokerage firm has set a target price of Rs 1660 for Sun Pharma shares, indicating a potential upside of approximately 2.2% from the current levels. This buy call is based on the company's strong fundamentals, growth prospects, and attractive valuation. Sun Pharma is a leading global pharmaceutical company with a diversified product portfolio and a strong presence in emerging markets.
About Sun Pharmaceutical Ind L:
Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a global specialty generic and branded pharmaceutical company headquartered in Mumbai, India. It is the world's third-largest generic pharmaceutical manufacturer by sales and a market leader in India. Sun Pharma manufactures and markets a wide range of generic, branded generic, and branded formulations, including anti-infectives, cardiovascular, central nervous system, gastrointestinal, oncology, and respiratory products. The company has a large network of manufacturing facilities across India, the US, Canada, Hungary, Romania, and Bangladesh. Sun Pharma also has a strong presence in emerging markets, including Latin America, Africa, Asia, and the Middle East.
52 Week Price Trend:
Sun Pharmaceutical Ind L (NSE:SUNPHARMA) is currently trading at Rs 1623.5, well above its 52-week low of Rs 922.45, but still below its 52-week high of Rs 1568.45. The stock has witnessed significant volatility over the past year, driven by factors such as the impact of the COVID-19 pandemic on the healthcare industry, regulatory challenges, and geopolitical uncertainties. Despite the challenges, Sun Pharmaceutical continues to be a leading player in the global pharmaceutical market, with a strong product portfolio and presence in key therapeutic areas. The company's long-term growth prospects remain promising, and the stock may continue to be a potential investment opportunity for investors with a long-term investment horizon.
Stratzy's MOST Analysis:
SunPharma has been rated AAA by Stratzy's MOST framework, indicating extremely low fundamental risk. This rating is based on an assessment of the company's management, outlook, safety, and trend. SunPharma's strong management team, positive industry outlook, financial stability, and consistent growth trajectory contribute to its exceptional rating. This indicates SunPharma is a well-run company with a solid financial foundation and a promising future, making it a low-risk investment option.
Company's Fundamentals:
Shares of Sun Pharmaceutical Industries Limited (SUNPHARMA) are priced at a Stock PE multiple of 39.9, indicating that investors are willing to pay 39.9 times the company's earnings for each share. The Price to Book (PB) Ratio is 6.24, signifying that the market value of SUNPHARMA is about 6.24 times the value of its assets per share. The low Dividend Yield of 0.74% suggests that the company is not distributing a significant portion of its earnings to shareholders in the form of dividends. This implies that SUNPHARMA may be prioritizing reinvestment in the business over dividend payments.
Fundamental and Technical information provided in this blog were last updated on 25 Jul, 2024
Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.